Compare CHR & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHR | JAGX |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 3.9M |
| IPO Year | N/A | N/A |
| Metric | CHR | JAGX |
|---|---|---|
| Price | $0.04 | $1.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | ★ 60.7M | 380.3K |
| Earning Date | 07-30-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.92 | N/A |
| Revenue | ★ $147,134,000.00 | $11,785,000.00 |
| Revenue This Year | N/A | $22.41 |
| Revenue Next Year | N/A | $30.00 |
| P/E Ratio | $0.02 | ★ N/A |
| Revenue Growth | N/A | ★ 12.45 |
| 52 Week Low | $0.03 | $1.00 |
| 52 Week High | $2.97 | $33.25 |
| Indicator | CHR | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 29.21 | 47.04 |
| Support Level | $0.04 | $1.05 |
| Resistance Level | $0.06 | $1.36 |
| Average True Range (ATR) | 0.01 | 0.14 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 34.95 | 70.00 |
Cheer Holding Inc is a provider of next generation mobile internet infrastructure and platform services in China. It is engaged in building a digital ecosystem that integrates platforms, applications, technology, and industry into a cohesive system, thereby creating a new, open business environment that leverages AI technology. Its portfolio includes various products and services, such as Polaris Intelligent Cloud, CHEERS Telepathy, CHEERS Open Platform, CHEERS Video, CHEERS e-Mall, CheerReal, CheerCar, CheerChat, CHEERS Fresh Group-Buying E-commerce Platform, Digital Innovation Research Institute, CHEERS Livestreaming, variety show series, IP short video matrix, and more.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.